Korea’s Celltrion issues $300 million CB

The deal is well-received, particularly by outright investors who see good growth potential for the Kosdaq-listed developer of biologic drugs.

Korea’s Celltrion issues $300 million CB

Korean biopharmaceutical company Celltrion last night raised $300 million from a convertible bond to fund product development, raw materials costs and other working capital requirements. The company, which is listed on Kosdaq, doesn’t have any outstanding debt in the international markets and this was its debut CB.

The deal has a five-year maturity but can be put back to the company at par on the third anniversary. Like other Korean CBs it has a...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition